Novartis’ Post

😎 Congratulations! Our client published an article in #Cell! #Immune-#checkpoint blockade has revolutionized cancer treatment, but some cancers, such as acute myeloid leukemia (#AML), do not respond or develop resistance. The study defined a membrane-associated MHC-I inhibitory axis as a potential therapeutic target for both leukemia and solid cancers. Mechanistically, #SUSD6 forms a trimolecular complex with #TMEM127 and MHC-I, which recruits #WWP2 for MHC-I ubiquitination and lysosomal degradation. Besides, the study shows that targeting SUSD6/TMEM127/WWP2 axis promotes T cell activity and enhances anti-cancer immunity in leukemia and solid cancers. https://lnkd.in/gPiamUxB For more push, please follow #Twitter: https://lnkd.in/gntQ9qE7 #Bafilomycin A1 (https://lnkd.in/g4-ZJJtb) was purchased from MedChemExpress.

November is #PancreaticCancerAwarenessMonth. Pancreatic cancer has very poor survival rates. Our scientists are dedicated to researching which genes🧬are involved in this type of cancer and find new approaches to treatment. Our work also aims to transform the landscape for patients with pancreatic cancer by making the most innovative new drugs available to patients as quickly as possible, and ensuring treatments are developed for those cancers that have yet to benefit significantly from modern advances in precision medicine. Learn more⬇️ https://lnkd.in/enhmHwwQ

Just released on Jama, Nov 28. Opinion on the phase III randomized trial of chemo-immunotherapy vs chemotherapy in first-line rec/met nasopharyngeal cancer (JUPITER-02). Overall, 37% reduction of risk of death at 3 years. To be discussed: - the lack of mainteinance therapy in chemotherapy only arm - the importance of EBV DNA dynamic - no role for PD-L1 expression as predictive factor - less evidence in de novo metastatic pts - applicability in non-endemic settings An important step in the treatment of NPC cancer pts!

The global incidence of early-onset cancer increased by 79.1%, and early-onset cancer deaths rose by 27.7% from 1990 to 2019, according to a 2023 study in the journal BMJ. Can you be prepared if cancer strikes? Call (246) 231-2045 to learn more.

🎖️Check out the Editor's Choice #Article "Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer" 👏Authors: Houssein Chhouri, PhD et al. INSERM 📌Link here: https://lnkd.in/dyWdNCHx ✨EGFR targeted inhibitors have become well-established treatments for EGFR-mutant non-small cell lung cancers. However, drug resistance frequently develops resulting in relapse. This review describes the four generations of EGFR inhibitors that have been developed and discusses the mechanisms of resistance that can arise on treatment and the strategies developed to circumvent them✨

EGFR mutations in non-small-cell lung cancer (#NSCLC) are twice as common among Asian patients compared to Caucasian patients, posing a significant management challenge. Two presentations at #ESMOAsia23 provide insights into recent treatment options. The subgroup analysis of Asian patients in the MARIPOSA-2 trial supports the main trial analysis showing a significant improvement in PFS with amivantamab plus chemotherapy compared to chemotherapy alone in patients progressing on osiemrinib. An exploratory analysis of the FLAURA2 trial suggested that the addition of platinum-based chemotherapy to first-line osimertinib did not impact acquired resistance mechanisms and should not influence targeted second-line treatment options. To learn more about this topic, and the challenges ahead in EGFR-mutated #NSCLC, read the # ESMODailyReporter article commented by Antonio Passaro 👉https://ow.ly/CR9B50QeLri

November was #lungcancerawarenessmonth, but months passing by shouldn't take away our motivation to find more effective and less toxic treatments for people affected by this condition. These are the first results of #AFM24 in NSCLC, and I feel incredibly proud to work with a team that has this "mantra" in mind (more effective but also less toxic), puts patients first, and wakes up every day willing to abate this disease. #innateimmunity #immunotherapy #oncology #clinicaltrials #clinicalresearch #NSCLC

The global incidence of early-onset cancer increased by 79.1%, and early-onset cancer deaths rose by 27.7% from 1990 to 2019, according to a 2023 study in the journal BMJ. Can you be prepared if cancer strikes? Call (246) 231-2045 to learn more.

The global incidence of early-onset cancer increased by 79.1%, and early-onset cancer deaths rose by 27.7% from 1990 to 2019, according to a 2023 study in the journal BMJ. Can you be prepared if cancer strikes? Call (246) 231-2045 to learn more.

How does smoking cause lung cancer? Good question to ask during Lung Cancer Awareness Month. According to a new study that analyzed 12,000 tumor samples, tobacco smoking is linked to something called "stop-gain mutations" (SGMs) that interfere with the formation of tumor suppressor genes, which help keep abnormal cells in check. These harmful protein-truncating mutations appear to contribute to the development of cancer and its increasing complexity over time. For the study published online in Science Advances, see https://lnkd.in/g3UmH8qB For a news story about the study, see https://bit.ly/3uqjTrL #lungcancer #stopsmoking #cypathlung #screeningsaveslives #earlydetection #cancerdiagnostics